XIENCE Prime™ BTK Everolimus Eluting Peripheral Stent System

XIENCE Prime™ BTK Everolimus Eluting Peripheral Stent System

The Next Step in BTK Efficacy.

XIENCE Prime™ BTK Everolimus Eluting Peripheral Stent System is clinically proven for primary stenting of focal and long lesions and is engineered for outstanding performance.1,2

Advancing BTK efficacy

Clinically Proven

  • Excellent long-term patency (angiographic binary in-stent restenosis (>50% stenosis)) of 85.2% and 98.7% limb salvage at 1 year.3,4
Xience Prime BTK Pre-procedure


Xience Prime BTK Post-procedure


Xience Prime BTK 12 Months Post-procedure

    12 months post-procedure4

Advancing BTK Efficacy

Engineered for outstanding performance

  • Leading MULTI-LINK stent design for exceptional acute performance, uncompromised radial force, and visibility5
  • Coating technology for reliable expansion and controlled Everolimus drug release
  • Innovative delivery system for excellent deliverability and confident deployment
Xience Prime BTK Engineering

Ordering Information

XIENCE Prime™ BTK Peripheral Stent System
Stock Number
Stent Diameter (mm)Stent Length (mm)Nominbal Pressure (ATM)
RBP (ATM)Max Stent Expansion Diameter (mm)




  1. Bosiers, M et al. Randomized comparison of everolimus-eluting versus bare-metal stents in patients with critical limb ischemia and infrapopliteal arterial occlusive disease; J Vascular Surgery 2012;55:390-399.
  2. Bosier, M et al.Outcome of a drug eluted stent in longer below the knee lesions in patients with critical limb ischemia: J Vascular Surgery 2017;58(1):49-54
  3. M. Bosiers, DESTINY, VEITH 2010
  4. M. Bosiers, LINC 2011
  5. Tests and data on file at Abbott

MAT-2115185 v1.0